Publications

Detailed Information

Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival

DC Field Value Language
dc.contributor.authorChoi, Yoon-La-
dc.contributor.authorOh, Ensel-
dc.contributor.authorPark, Sarah-
dc.contributor.authorKim, Yeonju-
dc.contributor.authorSong, Kyoung-
dc.contributor.authorHong, Yun-Chul-
dc.contributor.authorLee, Jeong Eon-
dc.contributor.authorNam, Seok Jin-
dc.contributor.authorYang, Jung-Hyun-
dc.contributor.authorShin, Young Kee-
dc.contributor.authorIm, Young-Hyuck-
dc.contributor.authorKim, Jung Han-
dc.contributor.authorChoi, Jong Sun-
dc.contributor.authorCho, Eun Yoon-
dc.contributor.authorPark, Yeon-Hee-
dc.date.accessioned2012-06-27T05:16:27Z-
dc.date.available2012-06-27T05:16:27Z-
dc.date.issued2010-09-23-
dc.identifier.citationBMC CANCER; Vol.10 ;507ko_KR
dc.identifier.issn1471-2407-
dc.identifier.urihttps://hdl.handle.net/10371/77572-
dc.description.abstractBackground: Triple-negative breast cancers (TNBCs) and basal-like breast cancers (BLBCs) are known as poor outcome subtypes with a lack of targeted therapy. Previous studies have shown conflicting results regarding the difference of prognostic significance between TNBCs and BLBCs. In this study, we aimed to characterize the prognostic features of TNBCs, in view of BLBCs and quintuple-negative breast cancers (QNBC/5NPs). Methods: Using tissue microarray-based immunohistochemical analysis, we categorized 951 primary breast cancers into four or five subtypes according to the expression of ER, PR, HER2, and basal markers (CK5/6, EGFR). Results: The results of this study showed that both TNBCs and BLBCs were associated with high histological and/or nuclear grades. When the TNBCs are divided into two subtypes by the presence of basal markers, the clinicopathologic characteristics of TNBCs were mainly maintained in the BLBCs. The 5-subgrouping was the better prediction model for both disease free and overall survival in breast cancers than the 4-subgrouping. After multivariate analysis of TNBCs, the BLBCs did not have a worse prognosis than the QNBC/5NPs. Interestingly, the patients with BLBCs showed significant adjuvant chemotherapy benefit. In addition, QNBC/5NPs comprised about 6 similar to 8% of breast cancers in publicly available breast cancer datasets Conclusion: The QNBC/5NP subtype is a worse prognostic subgroup of TNBCs, especially in higher stage and this result may be related to adjuvant chemotherapy benefit of BLBCs, calling for caution in the identification of subgroups of patients for therapeutic classification.ko_KR
dc.language.isoenko_KR
dc.publisherBIOMED CENTRAL LTDko_KR
dc.titleTriple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survivalko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor최윤라-
dc.contributor.AlternativeAuthor박사라-
dc.contributor.AlternativeAuthor김연주-
dc.contributor.AlternativeAuthor박연희-
dc.contributor.AlternativeAuthor송경-
dc.contributor.AlternativeAuthor조은윤-
dc.contributor.AlternativeAuthor홍윤철-
dc.contributor.AlternativeAuthor최종선-
dc.contributor.AlternativeAuthor이정언-
dc.contributor.AlternativeAuthor김정한-
dc.contributor.AlternativeAuthor남석진-
dc.contributor.AlternativeAuthor임영혁-
dc.contributor.AlternativeAuthor양정현-
dc.contributor.AlternativeAuthor신영기-
dc.identifier.doi10.1186/1471-2407-10-507-
dc.citation.journaltitleBMC CANCER-
dc.description.citedreferenceRakha EA, 2009, CLIN CANCER RES, V15, P2302, DOI 10.1158/1078-0432.CCR-08-2132-
dc.description.citedreferenceIrvin WJ, 2008, EUR J CANCER, V44, P2799, DOI 10.1016/j.ejca.2008.09.034-
dc.description.citedreferenceRhee JY, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-307-
dc.description.citedreferenceNishimura R, 2008, BREAST CANCER-TOKYO, V15, P303, DOI 10.1007/s12282-008-0042-3-
dc.description.citedreferenceTan DSP, 2008, BREAST CANCER RES TR, V111, P27, DOI 10.1007/s10549-007-9756-8-
dc.description.citedreferenceBertucci F, 2008, INT J CANCER, V123, P236, DOI 10.1002/ijc.23518-
dc.description.citedreferenceRakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748-
dc.description.citedreferenceCheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658-
dc.description.citedreferenceRakha E, 2008, CLIN CANCER RES, V14, P618, DOI 10.1158/1078-0432.CCR-07-1943-
dc.description.citedreferenceConforti R, 2007, ANN ONCOL, V18, P1477, DOI 10.1093/annonc/mdm209-
dc.description.citedreferenceFadare O, 2007, ADV ANAT PATHOL, V14, P358-
dc.description.citedreferenceTischkowitz M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-134-
dc.description.citedreferenceCarey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109-
dc.description.citedreferenceKreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771-
dc.description.citedreferenceRakha EA, 2007, CANCER, V109, P25, DOI 10.1002/cncr.22381-
dc.description.citedreferenceKim MJ, 2006, HUM PATHOL, V37, P1217, DOI 10.1016/j.humpath.2006.04.015-
dc.description.citedreferenceCarey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492-
dc.description.citedreferenceRouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421-
dc.description.citedreferenceWang YX, 2005, LANCET, V365, P671-
dc.description.citedreferenceNielsen TO, 2004, CLIN CANCER RES, V10, P5367-
dc.description.citedreferenceRosen DG, 2004, MODERN PATHOL, V17, P790, DOI 10.1038/modpathol.3800120-
dc.description.citedreferenceYaziji H, 2004, JAMA-J AM MED ASSOC, V291, P1972-
dc.description.citedreferenceAhn SH, 2004, ARCH SURG-CHICAGO, V139, P27-
dc.description.citedreferenceSorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100-
dc.description.citedreferencevan de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999-
dc.description.citedreferenceVANTVEER, 2002, NATURE, V415, P530-
dc.description.citedreferenceHarvey JM, 1999, J CLIN ONCOL, V17, P1474-
dc.description.citedreferenceSILVER DP, J CLIN ONCOL, V28, P1145-
dc.description.tc4-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share